Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma

NCT04505813 is registered in ClinicalTrials.gov with NexImmune Inc. as lead sponsor.

NCT NCT04505813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04505813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Lead sponsor
NexImmune Inc.
Phase
Phase 1/2
Overall status
Suspended
Start date
August 17, 2020
Completion date
December 31, 2025
Enrollment
9 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed refractory multiple myeloma